Evaluating the effect of Alantolactone on the expression of N-cadherin and Vimentin genes effective in epithelial-mesenchymal transition (EMT) in breast cancer cell line (MDA-MB-231)
Open Access
- 4 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 73, 103240
Abstract
Objective: Breast cancer is the second leading cause of death and the most common cancer among women. 10 to 20 percent of breast cancer samples have a negative triple phenotype that is more metastatic and more difficult to diagnose. Tumor invasion to other tissues and the formation of a secondary tumor depend on the epithelial to mesenchymal transition process, and the STAT3 pathway, which is associated with tumor proliferation and invasion and is the target gene for the drug, alantolactone. In this study, the EMT process is evaluated in negative triple-breasted cancer cells treated with alantolactone. Methods: We used MDA-MB-231 cell line for assessing the survival rate of triple negative breast cancer cells and MTT test for determining alantolactone dose. We used three doses of 0.01 0.1, and 1 mu M of alantolactone for evaluating the cell behavior in cancer invasion pathway. Real-time PCR was used to evaluate the expression of Vimentin, and N-cadherin genes. All of the tests were repeated thrice and the data were analyzed using Prism version 7.0. Results: The expression of Vimentin and N-cadherin decreased significantly at 1 mu M alantolactone compared to the control group, p < 0.05. Conclusion: Alantolactone affects the expression of Vimentin and N-cadherin through STAT3 signaling pathway and suppresses EMT process, metastasis and cancer invasion. This component may be used for treatment of patients with breast cancer.Keywords
Funding Information
- Urmia University of Medical Sciences
This publication has 26 references indexed in Scilit:
- Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cellsCancer Letters, 2015
- STAT3 and epithelial–mesenchymal transitions in carcinomasJAK-STAT, 2014
- Molecular mechanisms of epithelial–mesenchymal transitionNature Reviews Molecular Cell Biology, 2014
- Breast cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parametersIndian Journal of Cancer, 2013
- Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancerBritish Medical Bulletin, 2012
- Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix MetalloproteinasesCold Spring Harbor Perspectives in Biology, 2012
- Metastatic Triple-negative Breast CancerClinical Oncology, 2011
- Breast Cancer in Iran: An Epidemiological ReviewThe Breast Journal, 2007
- N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin ExpressionJournal of Cell Biology, 1999